Everything below concerns Proline-rich sequence. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-26. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
== Experimental chemistry == In 1995, the first report on attempted isolation of the element was unsuccessful, prompting new theoretical studies to investigate how best to investigate bohrium (using its lighter homologs technetium and rhenium for comparison) and removing unwanted contaminating elements such as the trivalent actinides, the group 5 elements, and polonium. In 2000, it was confirmed that although relativistic effects are important, bohrium behaves like a typical group 7 element. A team at the Paul Scherrer Institute (PSI) conducted a chemistry reaction using six atoms of 267Bh produced in the reaction between 249Bk and 22Ne ions. The resulting atoms were thermalised and reacted with a HCl/O2 mixture to form a volatile oxychloride. The reaction also produced isotopes of its lighter homologues, technetium (as 108Tc) and rhenium (as 169Re). The isothermal adsorption curves were measured and gave strong evidence for the formation of a volatile oxychloride with properties similar to that of rhenium oxychloride. This placed bohrium as a typical member of group 7. The adsorption enthalpies of the oxychlorides of technetium, rhenium, and bohrium were measured in this experiment, agreeing very well with the theoretical predictions and implying a sequence of decreasing oxychloride volatility down group 7 of TcO3Cl > ReO3Cl > BhO3Cl.
== Medical uses == Insulin degludec is indicated to improve glycemic control in people with diabetes. In a meta-analysis involving data from 3 randomized controlled trials having 1171 patients, thrice weekly insulin degludec had similar efficacy as daily insulin glargine injections with regards to the fasting blood glucose reduction, having similar safety and risk of low blood glucose (hypoglycaemia) profile. However the overall HbA1c reduction with thrice weekly insulin degludec injection was marginally lower than that of daily insulin glargine injections. Hence thrice weekly degludec injections can be considered in extremely needle prick phobic patients as a choice for basal insulin therapy.
=== Classification according to chemical structure === Most surfactants comprise "tails" based on saturated or unsaturated hydrocarbons. Fluorosurfactants have fluorocarbon chains. Siloxane surfactants have siloxane chains.
==== Asthma ==== Ketamine has been suggested as a possible therapy for children with severe acute asthma who do not respond to standard treatment. This is due to its bronchodilator effects in the respiratory system. A 2012 Cochrane review found there were minimal adverse effects reported, but the limited studies showed no significant benefit.
Calcitriol also reduces calcium loss to urine. Per the diagram, calcitriol suppresses the parathyroid hormone gene, thus creating a negative feedback loop that combines to tightly maintain plasma calcium in a normal range of 2.1-2.6 mmol/L for total calcium and 1.1-1.3 mmol/L for ionized calcium. However, there are also vitamin D receptors in bone cells, so that with serum vitamin D in great excess, osteoclastic bone resorption is promoted regardless of PTH, resulting in hypercalcemia and its symptomology.
Sources: en.wikipedia.org
In 2018, Trump signed into law the First Step Act which, among other federal prison reforms, made the 2010 Fair Sentencing Act retroactive. A US Supreme Court decision in 2021 determined that retroactivity applied to cases where mandatory minimum penalties had been imposed. In 2020, both the ACLU and The New York Times reported that Republicans and Democrats were in agreement that it was time to end the war on drugs. During his presidential campaign, President Joe Biden (2021–2025) stated that he would take the steps to alleviate the war on drugs and end the opioid epidemic. On December 4, 2020, during the Trump administration, the House of Representatives passed the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act), which would decriminalize cannabis at the federal level by removing it from the list of scheduled substances, expunge past convictions and arrests, and tax cannabis to "reinvest in communities targeted by the war on drugs". The MORE Act was received in the Senate in December 2020 where it remained. In April 2022, the act was again passed by the House, and awaits Senate action. Over time, states in the US have approached drug liberalization at a varying pace. Initially, in the 1930s, the states were ahead of the federal government in prohibiting cannabis; in recent decades, the trend has reversed. Beginning with cannabis for medical use in California in 1996, states began to legalize cannabis.
==== Central nervous system and appetite regulation ==== GLP-1 receptor activation stimulates satiety, thus reducing food intake, promoting the development of a negative energy balance, and decreasing body weight over time, making GLP-1 agonists a treatment option for obesity. In the hypothalamus, this is achieved by stimulating anorexigenic (satiety-inducing) POMC and CART neurons while simultaneously inhibiting orexigenic (appetite-inducing) AgRP and NPY neurons. GLP-1 agonists also counteract obesity-induced leptin resistance. They do this by downregulating inhibitory proteins like SOCS3 and PTP1B, which restores the brain's JAK/STAT signaling cascade and re-establishes sensitivity to leptin.
Cremasco, V., Woodruff, M. C., Onder, L., Cupovic, J., Nieves-Bonilla, J. M., Schildberg, F. A., Chang, J., Harvey, C. J., Wucherpfennig, B., Ludewig, B., Carroll, M. C., & Turley, S. J. (2014). B cell homeostasis and follicle confines are governed by fibroblastic reticular cells. Nature Immunology, 15(8), 973–981. https://doi.org/10.1038/ni.2965 Li, L., Lu, Y., Zhou, L., Shi, S., Zhu, X., & Zhang, L. (2021). Lymph node fibroblastic reticular cells steer immune responses. Trends in Immunology. https://doi.org/10.1016/j.it.2021.06.002 Link, A., Vogt, T. K., Favre, S., Britschgi, M. R., Acha-Orbea, H., Hinz, B., Cyster, J. G., & Luther, S. A. (2007). Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naïve T cells. Nature Immunology, 8(11), 1255–1265. https://doi.org/10.1038/ni1513 Lütge, M., Pikor, N. B., & Ludewig, B. (2021). Differentiation and activation of fibroblastic reticular cells. Immunological Reviews, 302(1), 32–46. https://doi.org/10.1111/imr.12981 Mueller, S. N., & Germain, R. N. (2015). Stromal cell contributions to the homeostasis and functionality of the immune system. Nature Reviews Immunology, 15(12), 729–740. https://doi.org/10.1038/nri3846 Onder, L., Papadopoulou, C., Lütge, A., Cheng, H.-W., Lütge, M., Perez-Shibayama, C., Gil-Cruz, C., De Martin, A., Kurz, L., Cadosch, N., Pikor, N. B., Rodriguez, R., Born, D., Jochum, W., Leskow, P., Dutly, A., Robinson, M. D., & Ludewig, B. (2025). Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer. Cell, 188(2), 430–446.
=== Steroids === Steroid injections have not been shown to have long term benefits for tendonitis, but appear to improve pain and function in the short term more effectively than other treatments except NSAIDs. They appear to have little benefit in tendinitis of the rotator cuff. There are some concerns that they may have negative effects.
Type XVIII collagen is a type of collagen which can be cleaved to form endostatin. The endostatin is from the c terminus end of the collagen XVIII, and is known to have an inhibitory effect on the growth of blood vessels. This is seen with tumors, where endostatin inhibits the growth of the blood vessels of the tumor as well as the overall growth of the tumor. The collagen XVIII is located within the basement membrane, and plays a major role in the integrity of the structure of the basement membrane for both endothelial and epithelial cells. The collagen XVIII has three different isoforms. While each of the isoforms has the same C-terminus end, they have a varying structure on the N-terminus end, which results in the formation of short, medium or long form Collagen XVIII.
Sources: en.wikipedia.org
== Structure == Type III collagen is synthesized by cells as a pre-procollagen; the human preproα1(III) chain is 1466 amino acids long, comprising an N-terminal signal peptide (residues 1–23), an N-terminal propeptide, the roughly 1000-residue triple-helical domain, and a C-terminal propeptide. The signal peptide is cleaved off producing a procollagen molecule. Three identical type III procollagen chains come together at the carboxy-terminal ends, and the structure is stabilized by the formation of disulphide bonds. Each individual chain folds into a left-handed helix and the three chains are then wrapped together into a right-handed superhelix, the triple helix. Prior to assembling the super-helix, each monomer is subjected to a number of post-translational modifications that occur while the monomer is being translated. First, on the order of 145 prolyl residues of the 239 in the triple-helical domain are hydroxylated to 4-hydroxyproline by prolyl-4-hydroxylase. Second, some of the lysine residues are hydroxylated or glycosylated, and some lysine as well as hydroxylysine residues undergo oxidative deamination catalysed by lysyl oxidase. Other post-translational modifications occur after the triple helix is formed. The large globular domains from both ends of the molecule are removed by C- and amino(N)-terminal-proteinases to generate triple-helical type III collagen monomers called tropocollagen. In addition, crosslinks form between certain lysine and hydroxylysine residues.
=== Abuse === Unlike other carbamates such as meprobamate and its prodrug carisoprodol, methocarbamol has greatly reduced abuse potential. Studies comparing it to the benzodiazepine lorazepam and the antihistamine diphenhydramine, along with placebo, find that methocarbamol produces increased "liking" responses and some sedative-like effects; however, at higher doses dysphoria is reported. It is considered to have an abuse profile similar to, but weaker than, lorazepam.
The death of Ali Khamenei triggered an election for a new supreme leader. Under the terms of Iran's constitution, the Interim Leadership Council was established on 1 March to exercise the functions of Iran's head of state until a new supreme leader is elected. Mojtaba Khamenei was elected on 8 March 2026 to replace his father as supreme leader, and the IRGC, as well as Iran's top leaders, including Mohammad Bagher Ghalibaf, Ali Larijani, and Masoud Pezeshkian, pledged their allegiance to him. In late March, the NYT described Iran's leadership as paralyzed with severely disrupted decision-making process. It also reported that the damage to communications infrastructure caused paranoia and internal power struggles. As of 21 May, Khamenei remains in hiding and the de facto ruler is uncertain. The IRGC is currently under command of the hardliner general Ahmad Vahidi, who is cited as the formulator of Iran's military and negotiation stance. The Telegraph has revealed a shadowy partnership with the retired IRGC commander-in-chief Mohammad Ali Jafari.
(2026) present a dataset of ages obtained through radiocarbon dating by accelerator mass spectrometry of bone collagen from remains of late Quaternary mammalian megafauna from Eurasia and North America. Review of advances in the study of paleogenomics of Chinese Quaternary proboscideans, even- and odd-toed ungulates and large carnivorans from the preceding years is published by Sheng et al. (2026). Köhler (2026) reviews the evolution of traits of organims from inland environments (including extinct Myotragus) that are adaptations to life in low-mortality isolated ecosystems with limited resources, and notes similarities with the evolution of traits of organisms adapted to life in caves. Schowanek et al. (2026) study factors influencing survival probability of mammals living in tropical forests of Africa, the Americas and the Indomalayan realm during the past 130,000 years, and report that analyses utilizing different statistical models recover similar predictors of extinction risk at the global scale, but recover variable predictors of extinction risk at smaller spatial scales. Kennedy & Sumanarathna (2026) present the first three-dimensional palaeoart reconstructions of Palaeoloxodon namadicus sinhaleyus and the Quaternary rhinoceros from the Sabaragamuwa Basin (Sri Lanka) historically referred to as Rhinoceros sinhaleyus. Faria et al.
== History and uses == Azinphos-methyl is a neurotoxin derived from nerve agents developed during World War II. It was first registered in the US in 1959 as an insecticide and is also used as active ingredient in organophosphate (OP) pesticides. It is not registered for consumer or residential use. It has been linked to health problems of farmers who apply it, and the U.S. Environmental Protection Agency (EPA) considered a denial of reregistration, citing, “concern to farm workers, pesticide applicators, and aquatic ecosystems. The use of AZM has been fully banned in the USA since 30 September 2013, ending a phase-out period of twelve years. Azinphos-methyl has been banned in the European Union since 2006 and in Turkey since 2013. The New Zealand Environmental Risk Management Authority made a decision to phase out azinphos-methyl over a five-year period starting from 2009. In 2014, it was still used in Australia and partly in New Zealand.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.